e-document prototype

I have spent the last 20 years researching and evolving an approach to designing and writing financial research documents which I call Message-based Design (MBD) & Message-based Writing (MBW). This is evidenced in the two A3 research background folders submitted on the theory behind Message-based Design & Writing. The output is a working prototype produced by a venture capitalist firm called 'Wicked Wisdom' based on my research. It is an e-document pioneering the way for research notes from Stockbrokers & Asset Management companies. It 'collapses out' from front to inside with video and sound, produced in flash and now being re-purposed in Java script. We need to radically re-think typography for text-rich business documents & publications (not referring to books). Most designers assume people have time to read. In reality the following occurs: Observations: 1) We browse/forage (71%) then read (11%) 2) People have different time tolerances and requirements for detail i.e. the same information is required to different levels of detailing dependent on the time the reader can allocate to it (Senior directors will have less time than juniors). 3) People want choice as to whether they wish to view information on paper, i-phone, PowerPoint or via web/screen. 4) Most publications do not follow the cognitive principles of how we are Œwired‚ to interpret visual signals. Message-based Design & Message-based Writing (MBD/MBW) is a system that addresses these 4 points and allows key messages to be understood prior to reading simply by scanning the page with its embedded Œvisual hooks‚ to draw the reader in. Thus it overcomes Œfilter failure‚ a phrase coined and first used by Clay Shirky at the Web 2.0 Expo. It collapses to a summary and exploits the way we are wired. Additionally it caters for up to 4 time tolerances of readers and morphs‚ from paper to screen effortlessly

Report of the Regional Co-ordination Meeting for the North Sea and Eastern Arctic (RCM NS&EA) 2016

The Regional Coordination Meeting NS&EA met in Edinburgh from 5th to 9th September 2016. Thirty four participants from 12 members states, representatives from Commission and ICES were in attendance. The meeting was largely devoted to subgroup work relating to regional sampling, cost sharing models, data needs and the sampling of anadromous and catadromous specie

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification